v3.26.3
(Loss) Earnings per Share - Schedule of Basic and Diluted (Loss) Earnings per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Numerator:        
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Denominator:        
Weighted-average shares outstanding - basic (in shares) 335,733 314,168 323,724 312,998
Effect of dilutive securities:        
Weighted-average shares outstanding - diluted (in shares) 335,733 324,754 335,233 323,704
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:        
Basic (in dollars per share) $ (0.06) $ 0.01 $ 0.30 $ 0.12
Diluted (in dollars per share) $ (0.06) $ 0.01 $ 0.29 $ 0.11
Stock options        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 882 767 981
Restricted stock units        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 4,129 4,192 4,303
Performance stock units        
Effect of dilutive securities:        
Effect of dilutive securities (in shares) 0 5,575 6,550 5,422